Low Albumin Associated With Early Mortality in AML

M. Alexander Otto, PA, MMS

July 12, 2022

The study covered in this summary was published on researchsquare.com as a preprint and has not yet been peer reviewed.

Key Takeaway

  • Low serum albumin is significantly associated with 60-day mortality in primary acute myeloid leukemia (AML).

Why This Matters

  • Early mortality is a substantial problem in AML.

  • The results suggest that patients with AML whose serum albumin level is <35 g/L are most at risk for earlier mortality and require particular attention.

Study Design

  • Serum albumin was measured after admission in 394 patients with primary AML from January 2013 to May 2021.

  • Multivariable Cox regression was used to determine the relationships between albumin and 60-day mortality.

Key Results

  • Overall, 60-day mortality was 43.8% for patients with a serum albumin <34.5 g/L; it was 27.5% for patients with albumin levels 34.5 – 38.5 g/L; and it was 16.5% for patients with levels ≥38.6 g/L.

  • After adjusting for confounders, the researchers observed a 9% decrease in the 60-day mortality rate with each 1 g/L increase in albumin (hazard ratio, 0.91; P = .001).


  • The study was retrospective and was limited to the Hakka population of southeastern China, a Han Chinese subgroup.

  • Unmeasured factors may have contributed to the increased risk of poor outcomes with low serum albumin.


  • There was no funding for the study; the investigators have disclosed no relevant financial relationships.

This is a summary of a preprint research study, "Association Between Serum Albumin and 60-Day Mortality in Chinese Hakka Patients With Non-APL Acute Myeloid Leukemia: A Retrospective Cohort Study," led by Zuomiao Xiao of the Affiliated Ganzhou Hospital of Nanchang University, China. The study has not been peer reviewed. The full text can be found at researchsquare.com.

M. Alexander Otto is a physician assistant with a master's degree in medical science and a journalism degree from Newhouse. He is an award-winning medical journalist who has worked for several major news outlets before joining Medscape and also an MIT Knight Science Journalism fellow. Email: aotto@mdedge.com.

For more news, follow Medscape on Facebook, Twitter, Instagram, and YouTube.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.